Polycystic Ovary Syndrome
Follicle Stimulating Hormone
Follicle Stimulating Hormone, Human
National Institute of Child Health and Human Development (U.S.)
Reproductive Techniques, Assisted
Histopathological findings of the ovaries in anovulatory women. (1/209)Wedge resection of the ovary was carried out in 45 anovulatory women to study the correlation between the degree of disturbance of ovulation and the histopathological findings. Polycystic ovary was always found in patients with anovulatory cycles. The ovaries in grade 1 amenorrhea showing withdrawal bleeding in response to gestagen alone belonged to the nonspecific type, polycystic type and sclerotic type. These histological changes were relatively mild in many cases. The ovaries in grade 2 amenorrhea showing withdrawal bleeding in response to estrogen and gestagen but not to gestagen alone belonged to the non-specific type, polycystic type, sclerotic type, atrophic type and streak type. Even within the same histological entity, the histological findings of the ovaries were more pronounced in grade 2 amenorrhea than in grade 1 amenorrhea. The patients with primary amenorrhea had only hypoplastic and aplastic ovaries with marked histological abnormalities. (+info)
Effects of time of suckling during the solar day on duration of the postpartum anovulatory interval in Brahman x Hereford (F1) cows. (2/209)Previously published reports have indicated that postpartum anovulatory intervals can be markedly reduced and rebreeding performance enhanced in Bos taurus cows by eliminating nighttime suckling. We sought to confirm this hypothesis by examining the effects of day, nighttime, and ad libitum suckling on suckling behavior of calves, duration of the postpartum anovulatory interval, and pregnancy rates in 45 fall-calving Brahman x Hereford (F1) cows. Beginning on d 9 to 12 postpartum, calves were removed from lactating cows from 0700 to 1900 (Night-Suckled, n = 15) or from 1900 to 0700 (Day-Suckled, n = 15), or remained with their dams continuously (Ad Libitum-Suckled, n = 15). Cows in each group were maintained with fertile Angus bulls from d 10 postpartum until the first normal luteal phase or 100 d postpartum, whichever occurred first. Cows were observed for estrous behavior twice daily, and jugular blood samples were collected twice weekly for the determination of serum progesterone concentration. Mean number of suckling episodes per 24 h was greater (P < .0001) for the Ad Libitum-Suckled group than either Night- or Day-Suckled groups (5.9+/-.42 vs 3.8+/-.14, and 3.9+/-.32, respectively). Hourly analysis of suckling episodes in the Ad Libitum group indicated that they were not skewed toward a particular period, with suckling occurring at a periodicity of 4 to 6 h. Intervals to the first rise in progesterone > or = 1 ng/mL (32+/-2.5, 32+/-4.5, and 31+/-1.7 d, respectively), first normal luteal phase (38+/-3.1, 38+/-3.8, and 37+/-2.5 d, respectively), and first estrus (43+/-3.5, 40+/-3.9, and 36+/-1.1 d, respectively) did not differ (P > .05) among the three groups. Similarly, cumulative pregnancy rates within 100 d after calving did not differ (P > .05). These results in Bos indicus x Bos taurus (F1) cattle do not support the previous conclusions in Bos taurus that eliminating nighttime suckling reduces the postpartum anovulatory interval. (+info)
Anovulations in an ovary during two menstrual cycles enhance the pregnancy potential of oocytes matured in that ovary during the following third cycle. (3/209)The aim of this study was to test whether ovulation from an ovary affects the health of oocytes from dominant follicles in that ovary two cycles later. A total of 80 women each with two intact ovaries underwent 270 treatment cycles (155 natural cycles and 115 clomiphene citrate cycles) all showing unilateral ovulation. The results from the in-vitro fertilization (IVF) treatment were grouped according to whether ovulation (O) or anovulation (A) (no ovulation) was observed in the ovary with dominant follicle during the treatment cycle in the previous two cycles: O-O, A-O, O-A and A-A (previous second cycle-previous first cycle). The rate of pre-embryo formation in A-A was significantly higher than that of O-A. The pregnancy rate in A-A (29%) was also higher than those of O-A (13%), A-O (9%) and O-O (5%). These rates increased from O-O to A-A as the number of previous ovulations in an ovary decreased. The presence of a corpus luteum and/or a dominant follicle is likely to exert local negative effects on the health of the oocyte contained in the follicle selected to ovulate up to two cycles later. Anovulations in an ovary for two menstrual cycles may therefore provide improved conditions for the development of a healthier oocyte with an increased pregnancy potential. (+info)
Nutritionally induced anovulation in beef heifers: ovarian and endocrine function preceding cessation of ovulation. (4/209)Angus x Hereford heifers were used to determine endocrine and ovarian function preceding nutritionally induced anovulation. Six heifers were fed to maintain body condition score (M), and 12 heifers were fed a restricted diet (R) until they became anovulatory. Starting on d 13 of an estrous cycle, heifers were given PGF2alpha every 16 d thereafter to synchronize and maintain 16 d estrous cycles. Ovarian structures of M and R heifers were monitored by ultrasonography daily from d 8 to ovulation (d 1 of the subsequent cycle) until R heifers became anovulatory. Concentrations of LH and FSH were quantified in serum samples collected every 10 min for 8 h on d 2 and 15 (48 h after PGF2alpha), and estradiol and IGF-I were quantified in daily plasma samples from d 8 to 16 during the last ovulatory cycle (Cycle -2) and the subsequent anovulatory cycle (Cycle -1). During the last two cycles before anovulation, M heifers had 50% larger (P < .0001) ovulatory follicles than R heifers and 61% greater (P < .0001) growth rate of the ovulatory follicles. There was a treatment x cycle x day effect (P < .001) for concentrations of estradiol. The preovulatory increase in estradiol occurred in the R and M heifers during Cycle -2 but only in M heifers during Cycle -1. A treatment x cycle x day effect (P < .05) influenced LH concentrations. During Cycle -2, LH concentrations were similar for M and R heifers, but during Cycle -1, M heifers had greater LH concentrations than did R heifers. Concentrations of FSH were greater (P < .05) in R than M heifers after induced luteolysis when R heifers failed to ovulate. There was a treatment x cycle interaction (P < .05) for IGF-I concentrations, and M heifers had 4.7- and 8.6-fold greater IGF-I concentrations than did R heifers during Cycle -2 and -1, respectively. We conclude that growth rate and diameter of the ovulatory follicle, and concentrations of LH, estradiol, and IGF-I are reduced before the onset of nutritionally induced anovulation in beef heifers. (+info)
Induction of ovulation by Sairei-to for polycystic ovary syndrome patients. (5/209)In anovulatory patients ovulation is usually induced by clomiphene citrate (CC) or gonadotropin therapy, but in the case of polycystic ovary syndrome (PCOS), diagnosed by the presence of several micropolycysts in the ovaries and a high LH/FSH ratio in the serum, CC is only minimally effective, and side effects are often a problem with gonadotropin therapy. In the present study we administered a Chinese herbal medicine Sairei-to which appears to have a steroidal effect in anovulatory PCOS patients. As a result of the treatment, serum LH and the LH/FSH ratio significantly decreased (P<0.01) and the ovulatory rate was 70.6%. Serum testosterone levels were within normal limits before the treatment, and did not significantly change during the treatment. Sairei-to may therefore be useful for the treatment of anovulation in PCOS patients. (+info)
Twice daily suckling but not milking with calf presence prolongs postpartum anovulation. (6/209)Two experiments were conducted to determine whether milking beef cows two or five times daily in the presence or absence of their own nonsuckling calves would alter postpartum interval to first ovulation. Multiparous Angus x Hereford cow-calf pairs were assigned randomly between 13 and 18 d postpartum to treatments for 4 wk. In Exp. 1, pairs were assigned to six treatments: 1) calf was weaned permanently from its dam (CW; n = 9); 2) same as CW, but dam was milked twice daily (CW+2xM; n = 9); 3) calf was present continuously with its dam but restricted from contact with the udder (CR; n = 9); 4) same as CR, but dam was milked twice daily (CR+2xM; n = 9); 5) same as CR, but calf was allowed to suckle twice daily (CR+2xS; n = 8); and 6) calf was present continuously with its dam and suckled ad libitum (CP; n = 9). The interval from onset of treatments to first postpartum ovulation was shorter (P<.05) in the CW (14.1+/-3.1 d), CR (14.2+/-3.1 d), CW+2xM (13.0+/-3.1 d), and CR+2xM (17.2+/-3.1 d) than in the CP (34.7+/-3.1 d) and CR+2xS (33.9+/-3.3 d) treatments. Daily milk yield during treatment was greater (P<.01) for CR+2xM cows (7.1+/-.6 kg) than for CW+2xM cows (3.5+/-.6 kg). In Exp. 2, cow-calf pairs were assigned to three treatments: 1) CR+2xM (n = 10); 2) same as CR+2xM but cows were milked five times daily (CR+5xM; n = 10); or 3) CP (n = 10). The interval to first postpartum ovulation was shorter (P<.05) in the CR+2xM (23.6+/-3.5 d) and CR+5xM (26.1+/-3.7 d) treatments than in the CP (37.7+/-3.7 d) treatment. Daily milk yield during treatment was greater (P<.05) for CR+5xM cows (7.7+/-.6 kg) than for CR+2xM cows (6.4+/-.6 kg) by 17%. We conclude that suckling twice daily was sufficient to prolong postpartum anestrus as much as suckling ad libitum. Furthermore, milk removal by suckling, but not by milking two or five times daily, even in the presence of the cow's own nonsuckling calf, is essential to prolong postpartum anovulation. (+info)
Adipocyte insulin action following ovulation in polycystic ovarian syndrome. (7/209)The role of anovulation and insulin resistance in the pathogenesis of polycystic ovarian syndrome (PCOS) remains to be determined. The aim of this study was to investigate whether the metabolic abnormality of insulin resistance in PCOS reflects, rather than causes, the ovarian dysfunction. Eight subjects with classical PCOS were studied on two occasions. Adipocyte insulin sensitivity together with hormonal and metabolic changes were investigated in patients with PCOS following prolonged amenorrhoea and then again in the early follicular phase after ovulation. Insulin receptor binding in amenorrhoeic subjects with PCOS was low at 0.78 +/- 0.08% and this increased to 1.18 +/- 0.19% after an ovulatory cycle (P < 0.05). Maximal insulin stimulated 3-O-methylglucose uptake was 0.70 +/- 0. 14 during amenorrhoea and increased to 1.08 +/- 0.25 pmol/10 cm(2) cell membrane (P < 0.05). Plasma testosterone fell (4.0 +/- 0.4 to 2. 3 +/- 0.2 nmol/l; P < 0.001), luteinizing hormone fell (17.6 +/- 2.3 to 6.7 +/- 0.8 IU/l; P < 0.001) but plasma insulin concentrations remained unchanged following ovulation (14.6 +/- 1.9 and 15.7 +/- 3. 8 pmol/l during amenorrhoea and after ovulation respectively). The results of this study suggest that chronic anovulation per se appears to modify the factors contributing to cellular insulin resistance seen in PCOS. (+info)
Neonatal handling induces anovulatory estrous cycles in rats. (8/209)Since previous work has shown that stimulation early in life decreases sexual receptiveness as measured by the female lordosis quotient, we suggested that neonatal handling could affect the function of the hypothalamus-pituitary-gonadal axis. The effects of neonatal handling on the estrous cycle and ovulation were analyzed in adult rats. Two groups of animals were studied: intact (no manipulation, N = 10) and handled (N = 11). Pups were either handled daily for 1 min during the first 10 days of life or left undisturbed. At the age of 90 days, a vaginal smear was collected daily at 9:00 a.m. and analyzed for 29 days; at 9:00 a.m. on the day of estrus, animals were anesthetized with thiopental (40 mg/kg, ip), the ovaries were removed and the oviduct was dissected and squashed between 2 glass slides. The number of oocytes of both oviductal ampullae was counted under the microscope. The average numbers for each phase of the cycle (diestrus I, diestrus II, proestrus and estrus) during the period analyzed were compared between the two groups. There were no significant differences between intact and handled females during any of the phases. However, the number of handled females that showed anovulatory cycles (8 out of 11) was significantly higher than in the intact group (none out of 10). Neonatal stimulation may affect not only the hypothalamus-pituitary-adrenal axis, as previously demonstrated, but also the hypothalamus-pituitary-gonadal axis in female rats. (+info)
1. Polycystic ovary syndrome (PCOS): This is the most common cause of anovulation, affecting up to 75% of women with PCOS.
2. Hypothalamic dysfunction: The hypothalamus regulates hormonal signals that stimulate ovulation. Disruptions in these signals can lead to anovulation.
3. Thyroid disorders: Both hypothyroidism (underactive thyroid) and hyperthyroidism (overactive thyroid) can disrupt hormone levels and lead to anovulation.
4. Premature ovarian failure (POF): This condition is characterized by the premature loss of ovarian function before age 40.
5. Ovarian insufficiency: This occurs when the ovaries lose their ability to produce eggs, often due to aging or medical treatment.
6. Chronic diseases: Certain conditions like diabetes, hypertension, and obesity can increase the risk of anovulation.
7. Luteal phase defect: This occurs when the uterine lining does not properly thicken during the second half of the menstrual cycle, making it difficult for a fertilized egg to implant.
8. Ovulatory disorders: Disorders such as ovarian cysts, endometriosis, and pelvic inflammatory disease can interfere with ovulation.
9. Genetic factors: Some genetic mutations can affect ovulation, such as those associated with Turner syndrome or other rare genetic conditions.
10. Medications: Certain medications, such as hormonal contraceptives and antidepressants, can disrupt ovulation.
Anovulation is typically diagnosed through a combination of medical history, physical examination, and laboratory tests, including hormone levels and imaging studies. Treatment options for anovulation depend on the underlying cause and may include:
1. Hormonal medications to stimulate ovulation
2. Intrauterine insemination (IUI) or in vitro fertilization (IVF) to increase the chances of conception
3. Lifestyle modifications, such as weight loss and stress management
4. Surgery to correct anatomical abnormalities or remove any blockages in the reproductive tract
5. Assisted reproductive technologies (ART), such as IVF with egg donation or surrogacy.
It's important for women experiencing irregular periods or anovulation to seek medical attention, as timely diagnosis and treatment can improve their chances of conceiving and reduce the risk of complications during pregnancy.
1. Irregular menstrual cycles, or amenorrhea (the absence of periods).
2. Cysts on the ovaries, which are fluid-filled sacs that can be detected by ultrasound.
3. Elevated levels of androgens (male hormones) in the body, which can cause a range of symptoms including acne, excessive hair growth, and male pattern baldness.
4. Insulin resistance, which is a condition in which the body's cells do not respond properly to insulin, leading to high blood sugar levels.
PCOS is a complex disorder, and there is no single cause. However, genetics, hormonal imbalances, and insulin resistance are thought to play a role in its development. It is estimated that 5-10% of women of childbearing age have PCOS, making it one of the most common endocrine disorders affecting women.
There are several symptoms of PCOS, including:
1. Irregular menstrual cycles or amenorrhea
2. Weight gain or obesity
4. Excessive hair growth on the face, chest, and back
5. Male pattern baldness
6. Infertility or difficulty getting pregnant
7. Mood changes, such as depression and anxiety
8. Sleep apnea
PCOS can be diagnosed through a combination of physical examination, medical history, and laboratory tests, including:
1. Pelvic exam: A doctor will examine the ovaries and uterus to look for cysts or other abnormalities.
2. Ultrasound: An ultrasound can be used to detect cysts on the ovaries and to evaluate the thickness of the uterine lining.
3. Hormone testing: Blood tests can be used to measure levels of androgens, estrogen, and progesterone.
4. Glucose tolerance test: This test is used to check for insulin resistance, which is a common finding in women with PCOS.
5. Laparoscopy: A small camera inserted through a small incision in the abdomen can be used to visualize the ovaries and uterus and to diagnose PCOS.
There is no cure for PCOS, but it can be managed with lifestyle changes and medication. Treatment options include:
1. Weight loss: Losing weight can improve insulin sensitivity and reduce androgen levels.
2. Hormonal birth control: Birth control pills or other hormonal contraceptives can help regulate menstrual cycles and reduce androgen levels.
3. Fertility medications: Clomiphene citrate and letrozole are commonly used to stimulate ovulation in women with PCOS.
4. Injectable fertility medications: Gonadotropins, such as follicle-stimulating hormone (FSH) and luteinizing hormone (LH), can be used to stimulate ovulation.
5. Surgery: Laparoscopic ovarian drilling or laser surgery can improve ovulation and fertility in women with PCOS.
6. Assisted reproductive technology (ART): In vitro fertilization (IVF) and intracytoplasmic sperm injection (ICSI) can be used to help women with PCOS conceive.
7. Alternative therapies: Some complementary and alternative therapies, such as acupuncture and herbal supplements, may be helpful in managing symptoms of PCOS.
It is important for women with PCOS to work closely with their healthcare provider to develop a treatment plan that meets their individual needs and goals. With appropriate treatment, many women with PCOS can improve their menstrual regularity, fertility, and overall health.
There are several possible causes of hyperandrogenism, including:
1. Congenital adrenal hyperplasia (CAH): A genetic disorder that affects the production of cortisol and aldosterone hormones by the adrenal glands.
2. Polycystic ovary syndrome (PCOS): A hormonal disorder that affects women of reproductive age and is characterized by cysts on the ovaries, irregular menstrual cycles, and high levels of androgens.
3. Adrenal tumors: Tumors in the adrenal glands can cause excessive production of androgens.
4. Familial hyperandrogenism: A rare inherited condition that causes an overproduction of androgens.
5. Obesity: Excess body fat can lead to increased production of androgens.
The symptoms of hyperandrogenism can vary depending on the cause, but may include:
2. Hirsutism (excessive hair growth)
3. Virilization (male-like physical characteristics, such as deepening of the voice and clitoral enlargement in women)
4. Male pattern baldness
5. Increased muscle mass and strength
6. Irregular menstrual cycles or cessation of menstruation
8. Elevated blood pressure
9. Elevated cholesterol levels
Treatment options for hyperandrogenism depend on the underlying cause, but may include:
1. Medications to reduce androgen production or block their effects
2. Hormone replacement therapy (HRT) to restore normal hormone balance
3. Surgery to remove tumors or cysts
4. Weight loss programs to reduce excess body fat
5. Lifestyle changes, such as exercise and dietary modifications, to improve overall health.
It's important to note that hyperandrogenism can also be caused by other factors, such as congenital adrenal hyperplasia or ovarian tumors, so it's important to consult a healthcare professional for proper diagnosis and treatment.
Causes of Female Infertility
There are several potential causes of female infertility, including:
1. Hormonal imbalances: Disorders such as polycystic ovary syndrome (PCOS), thyroid dysfunction, and premature ovarian failure can affect hormone levels and ovulation.
2. Ovulatory disorders: Problems with ovulation, such as anovulation or oligoovulation, can make it difficult to conceive.
3. Tubal damage: Damage to the fallopian tubes due to pelvic inflammatory disease, ectopic pregnancy, or surgery can prevent the egg from traveling through the tube and being fertilized.
4. Endometriosis: This condition occurs when tissue similar to the lining of the uterus grows outside of the uterus, causing inflammation and scarring that can lead to infertility.
5. Fibroids: Noncancerous growths in the uterus can interfere with implantation of a fertilized egg or disrupt ovulation.
6. Pelvic adhesions: Scar tissue in the pelvis can cause fallopian tubes to become damaged or blocked, making it difficult for an egg to travel through the tube and be fertilized.
7. Uterine or cervical abnormalities: Abnormalities such as a bicornuate uterus or a narrow cervix can make it difficult for a fertilized egg to implant in the uterus.
8. Age: A woman's age can affect her fertility, as the quality and quantity of her eggs decline with age.
9. Lifestyle factors: Factors such as smoking, excessive alcohol consumption, and being overweight or underweight can affect fertility.
10. Stress: Chronic stress can disrupt hormone levels and ovulation, making it more difficult to conceive.
It's important to note that many of these factors can be treated with medical assistance, such as medication, surgery, or assisted reproductive technology (ART) like in vitro fertilization (IVF). If you are experiencing difficulty getting pregnant, it is recommended that you speak with a healthcare provider to determine the cause of your infertility and discuss potential treatment options.
Treatment for oligomenorrhea depends on the underlying cause, but may include hormone replacement therapy, birth control pills, or other medications to regulate menstrual cycles. In some cases, surgery may be necessary to correct anatomical abnormalities or remove cysts that are interfering with normal menstruation.
Oligomenorrhea can have significant impacts on women's lives, including difficulty becoming pregnant due to irregular ovulation and increased risk of developing endometrial cancer. Therefore, early diagnosis and treatment are important to manage the condition and prevent potential complications.
Some of the symptoms of hirsutism include:
* Thick, dark hair on the face, chest, back, and buttocks
* Hair growth on the arms, legs, and other areas of the body
* Thinning or loss of hair on the head
* Acne and oily skin
Hirsutism can be caused by a variety of factors, including:
* Hormonal imbalances: Excessive levels of androgens, such as testosterone, can cause hirsutism.
* Genetics: Inheritance plays a role in the development of hirsutism.
* Medications: Certain medications, such as anabolic steroids and certain antidepressants, can cause hirsutism as a side effect.
* Other medical conditions: Polycystic ovary syndrome (PCOS), congenital adrenal hyperplasia (CAH), and other endocrine disorders can also cause hirsutism.
There are several treatment options for hirsutism, including:
* Medications such as anti-androgens and retinoids to reduce hair growth and improve skin texture
* Electrolysis and laser therapy to remove unwanted hair
* Hormonal therapies such as birth control pills and spironolactone to regulate hormone levels and reduce hair growth
* Plastic surgery to remove excess hair-bearing skin.
It is important for individuals with hirsutism to seek medical attention if they experience any of the following symptoms:
* Sudden or excessive hair growth
* Hair growth on the face, chest, back, or buttocks
* Thinning or loss of hair on the head
* Acne and oily skin.
Early diagnosis and treatment can help manage the symptoms of hirsutism and improve quality of life for individuals affected by this condition.
There are several possible causes of amenorrhea, including:
1. Hormonal Imbalance: Imbalance of hormones can prevent the uterus from preparing for menstruation.
2. Pregnancy: Pregnancy is one of the most common causes of amenorrhea.
3. Menopause: Women going through menopause may experience amenorrhea due to the decreased levels of estrogen and progesterone.
4. Polycystic Ovary Syndrome (PCOS): PCOS is a hormonal disorder that can cause irregular periods or amenorrhea.
5. Thyroid Disorders: Both hypothyroidism (underactive thyroid) and hyperthyroidism (overactive thyroid) can cause amenorrhea.
6. Obesity: Women who are significantly overweight may experience amenorrhea due to the hormonal imbalance caused by excess body fat.
7. Stress: Chronic stress can disrupt hormone levels and cause amenorrhea.
8. Surgery or Trauma: Certain surgeries, such as hysterectomy or removal of the ovaries, can cause amenorrhea. Trauma, such as a severe injury or infection, can also cause amenorrhea.
9. Medications: Certain medications, such as steroids and chemotherapy drugs, can cause amenorrhea as a side effect.
10. Endocrine Disorders: Disorders such as hypogonadotropic hypogonadism, hyperprolactinemia, and hypothyroidism can cause amenorrhea.
Amenorrhea can cause a range of symptoms, including:
1. No menstrual period
2. Difficulty getting pregnant (infertility)
3. Abnormal vaginal bleeding or spotting
4. Painful intercourse
5. Weight gain or loss
6. Mood changes, such as anxiety or depression
10. Hot flashes
Amenorrhea is typically diagnosed based on a patient's medical history and physical examination. Additional tests may be ordered to determine the underlying cause of amenorrhea, such as:
1. Blood tests to measure hormone levels, including estrogen, progesterone, and thyroid-stimulating hormone (TSH)
2. Imaging tests, such as ultrasound or MRI, to evaluate the ovaries and uterus
3. Laparoscopy, a minimally invasive procedure that allows the doctor to visually examine the ovaries and fallopian tubes
4. Hysteroscopy, a procedure that allows the doctor to examine the inside of the uterus
The treatment of amenorrhea depends on the underlying cause. Some common treatments include:
1. Hormone replacement therapy (HRT) to restore hormone balance and promote menstruation
2. Medications to stimulate ovulation, such as clomiphene citrate or letrozole
3. Surgery to remove fibroids, cysts, or other structural abnormalities that may be contributing to amenorrhea
4. Infertility treatments, such as in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI), if the patient is experiencing difficulty getting pregnant
5. Lifestyle changes, such as weight loss or exercise, to improve overall health and promote menstruation
There is no specific way to prevent amenorrhea, but maintaining a healthy lifestyle and managing any underlying medical conditions can help reduce the risk of developing the condition. Some tips for prevention include:
1. Eating a balanced diet that includes plenty of fruits, vegetables, whole grains, and lean protein sources
2. Exercising regularly to maintain a healthy weight and improve overall health
3. Managing stress through relaxation techniques, such as yoga or meditation
4. Getting enough sleep each night
5. Avoiding excessive alcohol consumption and smoking
6. Maintaining a healthy body mass index (BMI) to reduce the risk of developing hormonal imbalances
7. Managing any underlying medical conditions, such as polycystic ovary syndrome (PCOS), thyroid disorders, or adrenal gland disorders
8. Avoiding exposure to harmful chemicals and toxins that can disrupt hormone balance.
Infertility can be classified into two main categories:
1. Primary infertility: This type of infertility occurs when a couple has not been able to conceive a child after one year of regular sexual intercourse, and there is no known cause for the infertility.
2. Secondary infertility: This type of infertility occurs when a couple has been able to conceive at least once before but is now experiencing difficulty in conceiving again.
There are several factors that can contribute to infertility, including:
1. Age: Women's fertility declines with age, especially after the age of 35.
2. Hormonal imbalances: Imbalances of hormones such as progesterone, estrogen, and thyroid hormones can affect ovulation and fertility.
3. Polycystic ovary syndrome (PCOS): A common condition that affects ovulation and can cause infertility.
4. Endometriosis: A condition in which the tissue lining the uterus grows outside the uterus, causing inflammation and scarring that can lead to infertility.
5. Male factor infertility: Low sperm count, poor sperm quality, and blockages in the reproductive tract can all contribute to infertility.
6. Lifestyle factors: Smoking, excessive alcohol consumption, being overweight or underweight, and stress can all affect fertility.
7. Medical conditions: Certain medical conditions such as diabetes, hypertension, and thyroid disorders can affect fertility.
8. Uterine or cervical abnormalities: Abnormalities in the shape or structure of the uterus or cervix can make it difficult for a fertilized egg to implant in the uterus.
9. Previous surgeries: Surgeries such as hysterectomy, tubal ligation, and cesarean section can affect fertility.
10. Age: Both male and female age can impact fertility, with a decline in fertility beginning in the mid-30s and a significant decline after age 40.
It's important to note that many of these factors can be treated with medical interventions or lifestyle changes, so it's important to speak with a healthcare provider if you are experiencing difficulty getting pregnant.
Pharmacodynamics of spironolactone
Feminizing hormone therapy
Medical uses of bicalutamide
Functional hypothalamic amenorrhea
Infertility in polycystic ovary syndrome
Sertoli-Leydig cell tumour
Leydig cell tumour
Estrogen insensitivity syndrome
Polycystic ovary syndrome
Lipoid congenital adrenal hyperplasia
Georgeanna Seegar Jones
Growth differentiation factor-9
Beginning of pregnancy controversy
Hypothalamic chronic anovulation - PubMed
The influence of sporadic anovulation on hormone levels in ovulatory cycles - PubMed
Cases reported • Anovulation
anovulation Archives - Dr. Masha, ND
Altered expression of IL-1ß, IL-1RI, IL-1RII, IL-1RA and IL-4 could contribute to anovulation and follicular persistence in...
Anorexia Nervosa: Practice Essentials, Background, Pathophysiology
Infertility | CDC
Pediatric Type 2 Diabetes Mellitus Clinical Presentation: History, Physical Examination
BRAVELLE®(urofollitropin for injection, purified)FOR SUBCUTANEOUS ORINTRAMUSCULAR INJECTION
The infertile couple: a cohort study in Duhok, Iraq
Serum progesterone: MedlinePlus Medical Encyclopedia
Difficulty Getting Pregnant: Boston IVF
Does stress affect your chances of getting pregnant? - Clearblue®
RFA-HD-13-016: Cooperative Multicenter Reproductive Medicine Network (U10)
Curriculum Vitae: Zhen Chen, Ph.D. | NICHD - Eunice Kennedy Shriver National Institute of Child Health and Human Development
Polycystic Ovary Syndrome A Review
FSH | Ask or chat with U.S. doctors on HealthTap
id|key id|primary name|gopher term class|icd9 code id|word synonyms|excluded from phr|excluded from cms|excluded from phr2...
Infertility: Symptoms, Causes, Treatment
Course Content - #91533: A Review of Infertility - NetCE
Chinese Medicine and Polycystic Ovarian Syndrome - Acufinder.com
Amenorrhea Treatment & Management: Approach Considerations, Treatment of Common Causes, Diet and Activity
What are the Links Between Polycystic Ovary Syndrome (PCOS) and Diabetes? - Blog - NIDDK
Environmental Medicine Course - CNM - Diploma Courses in Nutrition, Herbal Medicine, Acupuncture, and Natural Chef
Infertility - Learn about INFERTILITY TREATMENT and it's Causes
- Efficacy of different gonadotropin combinations to support ovulation induction in WHO type I anovulation infertility: clinical evidences of human recombinant FSH/human recombinant LH in a 2:1 ratio and highly purified human menopausal gonadotropin stimulation protocols. (nih.gov)
- Anatomic causes include: - ovarian factors, which are a major cause of infertility and are related to anovulation and oligoovulation (infrequent ovulation). (womens-health-club.com)
- With time, testosterone therapy often results in amenorrhea (no menstruation) and anovulation (no ovulation). (coastalfertility.com)
Lead to anovulation2
- Although used and Levator Ani Assay: The classic users have with increased adipose tissue anovulation, infertility and menstrual disturbances. (mamapundit.com)
- 1. [Treatment of the amenorrhea-galatorrhea-anovulation syndrome with bromocryptin and the results]. (nih.gov)
- or amenorrhea, or anovulation with scanty bleeding. (acufinder.com)
- Other than pregnancy, constitutional delay, anovulation, and chronic illness, most other disorders that cause amenorrhea may require referral to a subspecialist for treatment. (medscape.com)
- The impairment of progesterone-induced pituitary release of prolactin and gonadotropin in patients with hypothalamic chronic anovulation. (nih.gov)
- It is characterized by hyperandrogenism and chronic anovulation. (medscape.com)
- reproductive abnormalities leading often to chronic anovulation, which is characterized by not getting menses in a regular pattern. (nih.gov)
- Chandeying P, Pantasri T. Prevalence of conditions causing chronic anovulation and the proposed algorithm for anovulation evaluation. (nhi.no)
- If a woman does not respond to clomiphene, she may have very low FSH and estrogen levels, a condition known as hypothalamic anovulation. (pacificfertilitycenter.com)
- For the adolescent with constitutional delay and anovulation, the goal should be the restoration of ovulatory cycles. (medscape.com)
- She may also display subtle menstrual abnormalities, such as anovulation, luteal phase defects, and/or changes in cycle length, but not consider herself amenorrheic. (training-conditioning.com)
- Do ovulatory hormone profiles among healthy premenopausal women differ between women with and without sporadic anovulation? (nih.gov)
- Anovulation occurs sporadically in healthy premenopausal women, but the influence of hormones in a preceding cycle and the impact on a subsequent cycle's hormone levels is unknown. (nih.gov)
- Women suffering from anovulation miss on the basic criteria for being pregnant. (theburningear.com)
- heavy metals increase anovulation, impaired implantation and loss of foetal viability. (naturopathy-uk.com)
Polycystic ovary sy3
- Patients with chronic anovulation are at increased risk for endometrial hyperplasia and malignancy, and endometrial sampling is imperative. (medscape.com)
- Chronic anovulation due to CNS-hypothalamic-pituitary dysfunction. (medscape.com)
- reproductive abnormalities leading often to chronic anovulation, which is characterized by not getting menses in a regular pattern. (nih.gov)
- however, little is known with regard to associations with reproductive hormones or anovulation. (nih.gov)
- Dunaif A. Hyperandrogenic anovulation (PCOS): a unique disorder of insulin action associated with an increased risk of non-insulin-dependent diabetes mellitus. (medscape.com)
- Medical management of PCOS is aimed at the treatment of metabolic derangements, anovulation, hirsutism, and menstrual irregularity. (medscape.com)
- Blood cadmium and lead levels in relation to anovulation served as the motivating example, based on findings from the BioCycle Study (2005-2007). (nih.gov)
- We investigated whether intakes of dairy foods and specific nutrients were associated with reproductive hormone concentrations across the cycle and the risk of sporadic anovulation among healthy women. (nih.gov)